Advances in the Molecular Biology of Sarcoma and Drug Development
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 56
Special Issue Editors
Interests: sarcoma; molecular biology; kinases; drug development; multidrug resistance
Special Issue Information
Dear Colleagues,
Sarcomas are a diverse group of cancers arising from connective tissues, presenting significant challenges in drug development due to their rarity and heterogeneity. Traditional treatments have primarily involved surgery, radiation, and chemotherapy. Although the outcome and survival rate for some sarcoma subtypes have improved over time, the current treatment regimens remain efficaciously limited. Recurrent and metastatic diseases remain a major obstacle in clinic.
Recent advances in understanding the genetic and epigenetic alterations of sarcomas and the associated signaling pathways hold promise for precise diagnosis and drug development. In this Special Issue, experts in this field will review and discuss the advances in the molecular biology of sarcoma, drug development, and personalized medicine.
Prof. Dr. Francis Hornicek
Prof. Dr. Zhenfeng Duan
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- sarcoma
- sarcoma models
- kinases
- drug development
- multidrug resistance
- targeted therapy
- immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
